A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)

Primary Objective

A double blind comparison of enzalutamide plus pembrolizumab or placebo in patients with metastatic prostate cancer.

This Study is
No Longer Enrolling

Details
Age

Adult

Type of Study

Treatment

Locations

Highlands Ranch Hospital
University of Colorado Hospital

Study ID

Protocol Number: 19-0493

More information available at ClinicalTrials.gov: NCT03834493

Categories

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers